The expanded label removes a major prescribing barrier for caregivers of young children, potentially accelerating adoption of neffy in pediatric settings. Traders should monitor future earnings for prescription growth trends and payer coverage updates.
Price Chart
Executive Summary
ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (epinephrine nasal spray), allowing children weighing ≥33 lbs. to use the needle-free treatment regardless of age. The label update also includes more flexible storage and usage guidance, which may improve patient adherence and expand market access.
Key Facts
- FDA approved removal of age restriction for neffy 1 mg, now available to all patients weighing ≥33 lbs., including children under 4 years old.
- Label update includes flexible storage: can be carried in blister pack or carrying case; company will include a free carrying case with each prescription starting summer 2026.
- Additional updates: neffy can be used after thawing if frozen, withstands temperatures up to 122°F, and sniffing after dosing does not alter treatment protocol.
- Approximately 25% of patients needing epinephrine are children ≥33 lbs. and <66 lbs., including ~25% under age 4 — a key underserved population due to needle fear.
Financial Impact
Expanded eligible patient population could increase market penetration; no direct revenue figures provided but addresses a key barrier to adoption.
Risk Factors
- Market acceptance still depends on payer reimbursement and competition from established epinephrine auto-injectors.
- Forward-looking statements about adoption and benefits are speculative and subject to execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263722 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers